Ainos (AIMD) has released an update to notify the public and investors about a regulation fd disclosure.
Ainos, Inc. has recently announced its progress in the fight against COVID-19 by submitting a complete response to the U.S. FDA for its Phase 2 trial of VELDONA®, a low-dose oral interferon-alpha treatment aimed at alleviating mild COVID-19 symptoms. This move marks a significant step forward in the potential expansion of treatment options for the disease, capturing the attention of investors and healthcare watchers alike.
For further insights into AIMD stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
